Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000387808 | SCV000334141 | pathogenic | not provided | 2016-06-05 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000692104 | SCV000819912 | pathogenic | Familial aplasia of the vermis; Meckel-Gruber syndrome; Nephronophthisis | 2024-01-25 | criteria provided, single submitter | clinical testing | This sequence change affects a splice site in intron 20 of the CEP290 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CEP290 are known to be pathogenic (PMID: 16909394, 17345604, 20690115). This variant is present in population databases (rs747835249, gnomAD 0.005%). Disruption of this splice site has been observed in individuals with Leber congenital amaurosis (LCA) (PMID: 23847139, 28510626, 28660274). ClinVar contains an entry for this variant (Variation ID: 236466). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Blueprint Genetics | RCV000225427 | SCV001240406 | pathogenic | Retinal dystrophy | 2019-07-11 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000387808 | SCV001982098 | pathogenic | not provided | 2021-07-13 | criteria provided, single submitter | clinical testing | Canonical splice site variant in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 32865313, 23847139, 31589614, 27535533) |
Fulgent Genetics, |
RCV002503881 | SCV002808947 | pathogenic | Leber congenital amaurosis 10; Meckel syndrome, type 4; Senior-Loken syndrome 6; Joubert syndrome 5; Bardet-Biedl syndrome 14 | 2021-09-29 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003469117 | SCV004214867 | pathogenic | Bardet-Biedl syndrome 14 | 2023-10-13 | criteria provided, single submitter | clinical testing | |
Centre for Genomic Medicine, |
RCV000225427 | SCV000282572 | likely pathogenic | Retinal dystrophy | no assertion criteria provided | clinical testing | ||
Natera, |
RCV001271589 | SCV001452856 | pathogenic | Leber congenital amaurosis | 2020-09-16 | no assertion criteria provided | clinical testing |